Therapeutic Asset Ratings

13,145 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Donafenib Liver And Intrahepatic Bile Duct Neoplasm	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P2	B (57)
Donanemab Cognitive Disorder	Eli Lilly and Company	P2	B (57)
Doxycycline Non-Small Cell Lung Carcinoma	Janssen Research & Development, LLC	P2	B (57)
Dulaglutide Beta-Thalassemia Major	Ain Shams University	P2	B (57)
Durvalumab Lung Adenocarcinoma	University of British Columbia	P2	B (57)
Durvalumab Cancer	Inimmune Corporation	P2	B (57)
Durvalumab BRCA2-Related Cancer Predisposition	European Organisation for Research and Treatment of Cancer - EORTC	P2	B (57)
Durvalumab Cervical Cancer	Second Affiliated Hospital of Guangzhou Medical University	P2	B (57)
Durvalumab Nonpapillary Renal Cell Carcinoma	AstraZeneca	P2	B (57)
Durvalumab Metastatic Malignant Neoplasm In The Colon	University of Iowa	P2	B (57)
Durvalumab Digestive System Cancer	M.D. Anderson Cancer Center	P2	B (57)
Durvalumab Female Reproductive Organ Cancer	Institute of Cancer Research, United Kingdom	P2	B (57)
Durvalumab Kidney Cancer	Ajjai Alva, MD	P2	B (57)
Durvalumab Cutaneous Neuroendocrine Carcinoma	Ariceum Therapeutics GmbH	P2	B (57)
Durvalumab Primary Central Nervous System Lymphoma	Washington University School of Medicine	P2	B (57)
Duvelisib Peripheral T-Cell Lymphoma, Not Otherwise Specified	City of Hope Medical Center	P2	B (57)
(E)-3-(2-((5-(3-(Phenylsulfonamido)Phenyl)Pent-4-En-1-Yl)Oxy)Phenyl)Propanoic Acid Chemotherapy-Induced Neuropathy	Ono Pharmaceutical Co., Ltd.	P2	B (57)
Edotreotide Pancreatic Neuroendocrine Tumor	ITM Solucin GmbH	P2	B (57)
Edotreotide Neoplasm	MedSIR	P2	B (57)
Efimosfermin Metabolic Dysfunction-Associated Steatohepatitis	Boston Pharmaceuticals	P2	B (57)
Efx Metabolic Dysfunction-Associated Steatohepatitis	Akero Therapeutics, Inc	P2	B (57)
Emestedastat Major Depressive Disorder	Actinogen Medical	P2	B (57)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Urethra Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2	B (57)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Urinary Bladder Cancer	Fred Hutchinson Cancer Center	P2	B (57)
Engensis Amyotrophic Lateral Sclerosis	Helixmith Co., Ltd.	P2	B (57)

Showing 3051 to 3075 of 13,145 assets

PreviousPage 123 of 526Next